Navigation Links
Protherics Licenses its CoVaccine HT Adjuvant to Nobilon for Influenza Vaccine Indications
Date:9/25/2007

BOXMEER, The Netherlands and LONDON, September 26 /PRNewswire/ -- Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for use in pandemic influenza vaccines, and seasonal influenza vaccines in elderly people.

More than 300 million doses of seasonal influenza vaccine are produced each year globally, leaving a considerable shortfall in the event of a pandemic influenza outbreak. A powerful adjuvant, such as CoVaccine(TM), may reduce the amount of antigen required in a pandemic influenza vaccine, enabling rapid, large scale production in the event of a pandemic influenza outbreak and for planned stockpiling. In addition, the CoVaccine HT(TM) adjuvant may increase the potency of a seasonal influenza vaccine for elderly people, with impaired immune systems.

The licensing agreement gives Nobilon the exclusive, global rights excluding the US, to develop, manufacture and commercialize two new influenza vaccines containing CoVaccine HT(TM). Protherics will receive an upfront payment from Nobilon on signing the agreement. Protherics is also entitled to receive success related milestone payments and royalty payments on net sales by Nobilon.

Also announced today, Nobilon and a consortium of leading European vaccine experts has received a EUR3.5 million grant to help fund the development of a pandemic influenza vaccine containing CoVaccine HT(TM).

Han van den Bosch, director Research and Development of Nobilon commented: "We are delighted to have gained exclusive access to CoVaccine HT, a promising new adjuvant from Protherics, for use in our flu vaccines. The very encouraging results in preclinical experiments using Nobilon's influenza antigen produced by cell culture and Protherics' CoVaccine adjuvant, justifies further clini
'/>"/>

SOURCE N.V. Organon
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. GenTel licenses next generation cancer research
2. Third Wave licenses Innogenetics tech to settle lawsuit
3. WARF licenses patents for new glaucoma drug treatment
4. PKWARE Licenses Technology to Expand SecureZIP Standard
5. Mentor Licenses Botulinum From WARF and Plans Wisconsin Manufacturing Facility
6. New Mexico firm to make flu vaccine at Wisconsin BioManufacturing facility
7. Studies Offer New Insight into HIV Vaccine Development
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ael, December 2 Gamida Cell announ...inical (animal study) safety and,efficacy of a gen...eill,Cornell Medical College and Gamida Cell. The ...ias such as Cooley,s Anemia. , Gamida Cel..., ex vivo,populations of stem/progenitor cells. T...
(Date:12/2/2009)...wswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ:...armaceutical company focused on endocrine therapy ...nd Drug Administration (FDA) has granted Fast Trac...nhibitor compound, perifosine (KRX-0401), for the ... Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX),...
(Date:12/1/2009)...olomon announced that he has joined Carolina Eyeca...ite at www.DrKerrySolomon.com , which was develop...proven LASIK, lens implant, and cataract surgery e...is substantial contributions to improving vision c...K Surgeons, which screens LASIK surgeons based upo...
(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Emerging Clinical Trial Locations - E...althcare and regulatory environment ,, http:/...rial-Locations---Eastern-Europe-Market-dynamics-an...nt.html ,, Over the last decade pharmaceutical...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...L, Inc. (Amex:,ADL), headquartered in Tustin, Cali...ilin, China, through its wholly owned subsidiary J... biopharma company that,together with JPI, engages...proprietary pharmaceutical, health care and diagno...I,s subsidiary, JJB, won a supply contract,for the...
... Pharmaceuticals,Inc. (Amex: ANX ), a biopharmace... commercializing proprietary product candidates fo... announced today that Evan M. Levine, the,company,... position as,Chief Executive Officer and President...eptember 2006., The company also announced that J...
...re-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NA...ceutical and,medical device company, is scheduled ...eutical, Biotechnology and Medical Device Conferen...NY., Dr. William Hunter, Angiotech,s President an...on Tuesday, February 5, at the Grand Hyatt New,Yor...
Other Biology Technology:AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million 2ADVENTRX Announces Consolidation of Clinical and Management Positions 2ADVENTRX Announces Consolidation of Clinical and Management Positions 3
(Date:12/1/2009)...ner of the 2009 Inserm Grand Prix., Every year s...aying tribute to outstanding,work performed in it...ts, Inserm intends to,demonstrate the diversity a...ical, medical and,health research, and the creati...t and,drive this research each day. The Inserm 20...
(Date:12/1/2009)...t-and-run attacks by sharks can be solved with a n...nique chomp they put on their victims, according t...ert. , In a method analogous to analyzing human ...by precisely comparing shark bites to the jaws and...ess, director of the International Shark Attack Fi...
(Date:12/1/2009)...onash University-led international research team h... of the next generation of solar cells. , Scient...olleagues from the universities of Wollongong and ...d solar cells with a three-fold increase in energy...ported tandem dye-sensitised solar cells. , Lea...
Breaking Biology News(10 mins):Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Innovation puts next-generation solar cells on the horizon 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 1Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 3Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 4Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 5Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 6Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 7Abbott HIV Test Demonstrates Earlier Disease Detection 13141 1Abbott HIV Test Demonstrates Earlier Disease Detection 13141 2Abbott HIV Test Demonstrates Earlier Disease Detection 13141 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 1Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 2Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 4Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 5
...ational team of Mayo Clinic-led researchers is fir...he measles virus into a therapeutic killer that hu...ells only. Their research findings appear as an ad... , The researchers harnessed the viral trait for ...cted the virus to attack diseased, rather than hea...
...ing the value of good prenatal care, new research ...ve vulnerability that appears later during stress ...y of Colorado at Boulder have reported that rats w...dn,t learn as well as adult rats who were not infe... The research is in February,s Behavioral Neurosci...
...ng animals, Johns Hopkins researchers have discove...eviate HIV,s negative effects on the brain and cen...n though antiretroviral therapy controls the virus...ith simian immunodeficiency virus (SIV), a very cl...had less damage to brain cells, less brain inflamm...
Other Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
Yeast Nitrogen Base from Invitrogen
Streptavidin, PE conjugated/tagged from Invitrogen
Rabbit Anti-Human PVRL2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GIBCO AmnioMAX-C100 Basal Medium liquid from Invitrogen
Biology Products: